EUCTR2005-005094-30-LT进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - Factorial Study
Merck & Co., Inc0 个研究点目标入组 1,400 人开始时间: 2005年12月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia with LDL-C between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Catetory II) and triglycerides = 350 mg/dL.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study, patients with <80% compliance, patients with certain medical conditions including those with a history of CHD/CHD equivalent or diabetes, patients taking certain concomitant medications and/or with unstable doses of medications.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - Factorial StudyHypercholesterolaemiaMedDRA version: 8.0Level: LLTClassification code 10020603EUCTR2005-005094-30-SEMerck Sharp & Dohme (Sweden) AB1,400
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B (dosed as coadministered MK 0524A and simvastatin Tablets) in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - Factorial StudyHypercholesterolaemiaMedDRA version: 8.0 Level: LLT Classification code 10020603EUCTR2005-005094-30-GBMerck Sharp & Dohme Limited1,400
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - Factorial StudyMedDRA version: 8.0 Level: LLT Classification code 10020603HypercholesterolaemiaEUCTR2005-005094-30-DKMerck & co. Inc.1,400
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration ofMK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes MellitusMedDRA version: 7.0Level: LLTClassification code 10045242Type 2 Diabetes MellitusEUCTR2005-000407-34-HUMerck & Co., Inc.900
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes MellitusMedDRA version: 7.0 Level: LLT Classification code 10045242Type 2 Diabetes MellitusEUCTR2005-000407-34-LTMerck & Co., Inc.900